Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03763929 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke
A Phase 2 study, sponsored by Diffusion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03763929 is a Phase 2 study that was terminated before completion, run by Diffusion Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT03763929, a Phase 2 study, was terminated before completion, sponsored by Diffusion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will assess the potential efficacy and safety of TSC as early treatment for both ischemic and hemorrhagic stroke when administered while subject is in ambulance being transported to hospital.
Interventions
- OTHER Placebo
- DRUG Trans-Sodium Crocetinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2020-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03763929
The ClinicalTrials.gov registry entry for NCT03763929 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diffusion Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03763929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03763929 about?
NCT03763929 is a clinical study titled "Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke". This study will assess the potential efficacy and safety of TSC as early treatment for both ischemic and hemorrhagic stroke when administered while subject is in ambulance being transported to hospital.
What is the current status of trial NCT03763929?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-08-22. Estimated completion is 2020-10-19.
What interventions are being tested in trial NCT03763929?
The interventions under investigation include: Placebo (OTHER), Trans-Sodium Crocetinate (DRUG).
Who is sponsoring clinical trial NCT03763929?
This trial is sponsored by Diffusion Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.